Cholesterol cerivastatin

Fibrates are the most effective triglyceride-lowering agents and also raise HDL cholesterol levels. Combination therapy with a fibrate, particularly gemfibrozil, and a statin has been found to increase the risk for myopathy. Of the 31 rhabdomyolysis deaths reported with cerivastatin use, 12 involved concomitant gemfibrozil.25 Therefore, more frequent monitoring, thorough patient education, and consideration of factors that increase the risk as reviewed previously should be considered. 

It has been found that the 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) inhibitors statins (atorvastatin, pravastatin, and cerivastatin), widely prescribed cholesterol-lowering agents, are able to inhibit phorbol ester-stimulated superoxide formation in endothelial-intact segments of the rat aorta [64] and suppress angiotensin II-mediated free radical production [65]. Delbose et al. [66] found that statins inhibited NADPH oxidase-catalyzed PMA-induced superoxide production by monocytes. It was suggested that statins can prevent or limit the involvement of superoxide in the development of atherosclerosis. It is important that statin... 

Cerivastatin sodium Bay col Cholesterol lowerers Muscle weakening 1999 u.s. 2001 2... 

For instance, in September 2004, Bayer settled 2861 product liability cases for 1.09 billion for its cholesterol medicine cerivastatin (Baycol), which was linked to 100 deaths and withdrawn from market in 2001. In July 2004, the company settled 2771 cases for 1.06 billion. Bayer still has 7577 additional cases to settle (see Section 28.4.4.5 for additional information). In another example, a 1 billion jury verdict was upheld against Wyeth for its fenfluramine or dexfenfluramine and phentermine (Fen-Phen) drug combination, which was linked to primary pulmonary hypertension (PPH). Wyeth has set aside 16.6 billion to cover future liability on the drug (see Section 28.4.4.2 for more on this case). ... 

Baycol (cerivastatin, sold as Lipobay in Europe, Bayer) is a statin, a class of cholesterol-lower drugs. Statins are the most prescribed drugs in the United States, with more than 12 million people taking them, and more than 700,000 people in the United States taking cerivastatin. It received marketing approval on June 26, 1997 and was voluntarily removed from the market on August 8, 2001 because of its link to 100 deaths and several injuries from potentially the muscle disease rhabdomyolysis. The other statins — lovas-tatin (Mevacor Merck) pravastatin (Pravachol Bristol-Myers Squibb) simvastatin (Zocor Merck) fluvastatin (Lescol Novartis) atorvastatin (Lipitor Parke-Davis) rosuvastatin... 

Cerivastatin, a drug used to reduce blood cholesterol, is known to be exported by the MDR1 transporter at the canalicular membrane in the liver cells, which functions to eliminate the drug into the bile. If there is competition with another drug, this elimination is decreased, and... 

This effect was elicited by a daily dose of 40 mg of lovastatin, pravastatin, simvastatin, atorvastatin, and fluvastatin, and by a daily dose of 0.3 mg of cerivastatin in patients with hypercholesterolemia. Reductions in LDL cholesterol of 30 to 32 percent are more typical of once-daily treatment with lovastatin and twice-daily treatment with pravastatin. 

Other statins include simvastatin (also a lactone prodrug), pravastatin, atorvastatin, and cerivastatin (active form with open ring). The statins are the most important therapeutics for lowering cholesterol levels. Their notable cardiovascular protective effect, however, appears to involve additional actions. 

Simons, L.A., Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am. J. Cardiol, 90, 737, 2002. 

In all honesty, the drugs appear to be relatively safe as a class. They have been used for two decades and have been prescribed to many millions of men and women around the world. Studies have demonstrated that they can prevent heart attacks and strokes and save lives by dramatically reducing cholesterol. Obviously, there were terrible problems with cerivastatin (Baycol). And the British medical journal The Lancet has asked for a recall of rosuvastatin (Crestor), citing poor research data and potential side effects involving the liver and the kidneys and muscle damage. Consumer advocates in the United States have also called for FDA to reverse its approval. 

In one of our other studies [37], the 6 months therapy with 0,4 mg daily of other HMG-CoA-reductase inhibitor cerivastatin, which is more effective than pravastatin as cholesterol-lowering drug, sharply increased the level of LDL lipohydroperoxides in the blood plasma of patients [37] (Figure 18). At the same time administration of cerivastatin in combination with synthetic antioxidant probucol in daily dose 250 mg did not produce the increase of the LDL lipohydroperoxide level in the plasma during all time of the observation [37] (Figure 18). 

Cerivastatin. Ccrivasiatin (Baycol) is one of the newer agents in this class of cholesterol-lowering agents. It carries, however, a higher incidence of rhabdomyolysis and. as a result, was voluntarily withdrawn from the market by its manufacturer in 2001. 

Cerivastatin is a competitive inhibitor of HIVIG-CoA reductase, which is responsible for the conver sion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis by cerivastatin reduces the level of cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors. 

The ability of statins to lower hsCRP was first described for pravastatin using data accumulated in the Cholesterol and Recurrent Events (CARE) trial. These data were initially highly controversial because they suggested that statins have both hpid-lowering and antiinflammatory effects. However, confirmatory work rapidly showed the effect of statins on hsCRP to be a consistent and important class effect. Studies of atorvastatin, cerivastatin, lovastatin, pravastatin, and simvastatin have shown that, on average, median hsCRP concentrations decline 15% to 25% as early as 6 weeks after initiation of therapy. Importantly the magnitude of LDL cholesterol reduction caused by statin therapy is minimally correlated with the magnitude of hsCRP reduction. ... 

Baycol (cerivastatin) was developed by Bayer A.G. and approved by the FDA for use in the United States in 1997. It is a member of a class of cholesterol-lowering drugs that are commonly referred to as statins . Statins such as Baycol lower cholesterol levels by blocking a specific enzyme in the body that is involved in the synthesis of cholesterol. Although all statins have been associated with very rare reports of rhabdomyolysis, a muscle disorder, cases of fatal rhabdomyolysis in association with the use of Baycol have been reported significantly more frequently than for other approved statins. On 8 August 2001, Bayer announced that it was voluntarily withdrawing Baycol from the US market because of reports of sometimes fatal rhabdomyolysis. 

In a clinical study, plasma concentrations of the cholesterol-lowering drug cerivastatin were determined after oral administration of a 0.2 mg single dose of cerivastatin to 12 kidney transplant recipients and healthy volunteers [22]. The mean AUC value of cerivastatin (36.2ng/mlh) in the kidney transplant recipients with cyclosporin was approximately fourfold higher than that in healthy volunteers (9.5 ng/mlh) who received the same oral dose of cerivastatin without cyclosporin treatment [22]. Due to the almost complete absorption of cerivastatin after oral administration and the fact that cyclosporin does not affect the elimination half-life, the authors suggested that the increased AUC observed in transplant patients cannot be explained only by cyclosporin-based CYP3A inhibition [23]. 

Scheme 4.12 Examples of fluorine

Cerivastatin (Baycol) Cholesterol lowering Rhabdomyolysis Drug-drug interactions... 

Lovastatin (Mevacor ) (3), simvastatin (Zocor ) (15), pravastatin (Pravachol ) (19), atorvastatin (Lipitor ) (20), cerivastatin (Baycol , withdrawn on August 1, 2003) (21), and fluvastatin (Lescol ) (22) were introduced to lower total cholesterol levels, and especially LDL-cholesterol levels to prevent coronary heart disease. These HMG-CoA inhibitors inhibit de novo synthesis of cholesterol in the liver. The rate-limiting enzyme in cholesterol synthesis is HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate. The resulting decrease in hepatic cholesterol synthesis leads to increased synthesis of... 

Cholesterol synthesis inhibitor Lovastatin Atorvastatin, pravastatin Simvastatin, cerivastatin, fluvastatin... 

Statins are now amongst the most widely used drugs worldwide. They are highly effective in lowering cholesterol levels, and have been shown to be effective in the primary and secondary prevention of ischaemic heart disease. Statins, however, can cause muscle toxicity, which most commonly manifests as an asymptomatic rise in CPK, and in the most severe cases, can cause rhabdomyolysis and death (Fig. 3) (Laaksonen 2006). Cerivastatin was withdrawn in 2001 because of its propensity to... 

---